Troldborg A, Thiel S, Jensen L, Hansen S, Laska M J, Deleuran B, Jensenius J C, Stengaard-Pedersen K
Center of Cancer and Inflammation, Department of Rheumatology, Aarhus University Hospital, Aarhus University.
Institute of Clinical Medicine, Aarhus University.
Clin Exp Immunol. 2015 Nov;182(2):132-8. doi: 10.1111/cei.12678. Epub 2015 Aug 31.
The objective of this study was to explore the involvement of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1) and other pattern recognition molecules (PRMs) of the lectin pathway of the complement system in a cross-sectional cohort of systemic lupus erythematosus (SLE) patients. Concentrations in plasma of CL-L1, CL-K1, mannan-binding lectin (MBL), M-ficolin, H-ficolin and L-ficolin were determined in 58 patients with SLE and 65 healthy controls using time-resolved immunoflourometric assays. The SLE patients' demographic, diagnostic, clinical and biochemical data and collection of plasma samples were performed prospectively during 4 months. CL-L1, CL-K1 and M-ficolin plasma concentrations were lower in SLE patients than healthy controls (P-values < 0.001, 0.033 and < 0.001, respectively). H-ficolin concentration was higher in SLE patients (P < 0.0001). CL-L1 and CL-K1 plasma concentrations in the individuals correlated in both patients and controls. Patients with low complement component 3 (C3) demonstrated a negative correlation between C3 and CL-L1 and CL-K1 (P = 0.022 and 0.031, respectively). Patients positive for anti-dsDNA antibodies had lower levels of MBL in plasma than patients negative for anti-dsDNA antibodies (P = 0.02). In a cross-sectional cohort of SLE patients, we found differences in the plasma concentrations of CL-L1, CL-K1, M-ficolin and H-ficolin compared to a group of healthy controls. Alterations in plasma concentrations of the PRMs of the lectin pathway in SLE patients and associations to key elements of the disease support the hypothesis that the lectin pathway plays a role in the pathogenesis of SLE.
本研究的目的是在系统性红斑狼疮(SLE)患者的横断面队列中,探究补体系统凝集素途径中的肝脏凝集素1(CL-L1)、肾脏凝集素1(CL-K1)及其他模式识别分子(PRM)的参与情况。采用时间分辨免疫荧光分析法,测定了58例SLE患者和65名健康对照者血浆中CL-L1、CL-K1、甘露聚糖结合凝集素(MBL)、M-纤维胶凝蛋白、H-纤维胶凝蛋白和L-纤维胶凝蛋白的浓度。在4个月的时间里前瞻性地收集了SLE患者的人口统计学、诊断、临床和生化数据以及血浆样本。SLE患者血浆中CL-L1、CL-K1和M-纤维胶凝蛋白的浓度低于健康对照者(P值分别<0.001、0.033和<0.001)。SLE患者中H-纤维胶凝蛋白浓度较高(P<0.0001)。患者和对照者个体血浆中CL-L1和CL-K1浓度均具有相关性。补体成分3(C3)水平低的患者中,C3与CL-L1和CL-K1呈负相关(P值分别为0.022和0.031)。抗双链DNA(dsDNA)抗体阳性的患者血浆中MBL水平低于抗dsDNA抗体阴性的患者(P=0.02)。在SLE患者的横断面队列中,我们发现与健康对照组相比,CL-L1、CL-K1、M-纤维胶凝蛋白和H-纤维胶凝蛋白的血浆浓度存在差异。SLE患者凝集素途径PRM的血浆浓度改变及其与疾病关键要素的关联支持了凝集素途径在SLE发病机制中起作用这一假说。